A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human
- 13 May 2022
- journal article
- research article
- Published by Springer Nature in Drug Delivery and Translational Research
- Vol. 12 (9) , 2178-2186
Abstract
The use of nanoparticles (NPs) can support an enhancement of drug distribution, resulting in increased drug penetration into key tissues. Experimental in vitro data can be integrated into computational approaches to simulate NP absorption, distribution, metabolism and elimination (ADME) processes and provide quantitative pharmacokinetic predictions. The aim of this study is to develop a novel mechanistic and physiologically based pharmacokinetic (m-PBPK) model to predict the biodistribution of NPs focusing on Doxil. The main processes underpinning NPs ADME were represented considering molecular and cellular mechanisms such as stability in biological fluids, passive permeability and uptake activity by macrophages. A whole-body m-PBPK rat and human models were designed in Simbiology v. 9.6.0 (MATLAB R2019a). The m-PBPK models were successfully qualified across doxorubicin and Doxil® in both rat and human since all PK parameters AUC0-inf, Cmax, t1/2, Vd and Cl were within twofold, with an AUC0-inf absolute average-fold error (AAFE) value of 1.23 and 1.16 and 1.76 and 1.05 for Doxorubicin and Doxil® in rat and human, respectively. The time to maximum concentration in tissues for doxorubicin in both rat and human models was before 30 min of administration, while for Doxil®, the tmax was after 24 h of administration. The organs that accumulate most NP are the spleen, liver and lungs, in both models. The m-PBPK represents a predictive platform for the integration of in vitro and formulation parameters in a physiological context to quantitatively predict the NP biodistribution. Graphical abstract Schematic diagram of the whole-body m-PBPK models developed for Doxil® in rat and human physiology.Keywords
All Related Versions
Funding Information
- H2020 European Research Council (761104)
This publication has 25 references indexed in Scilit:
- An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometryCritical Reviews in Toxicology, 2012
- Doxil® — The first FDA-approved nano-drug: Lessons learnedJournal of Controlled Release, 2012
- Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and humanJournal of Pharmacokinetics and Pharmacodynamics, 2011
- Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeabilityJournal of Angiogenesis Research, 2010
- [186Re]Liposomal doxorubicin (Doxil): in vitro stability, pharmacokinetics, imaging and biodistribution in a head and neck squamous cell carcinoma xenograft modelNuclear Medicine and Biology, 2009
- Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimeticJournal of Controlled Release, 2005
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003
- Polyethylenglykol-umhülltes (pegyliertes) liposomales DoxorubicinDrugs, 1997
- Pharmacokinetics, Biodistribution and Therapeutic Efficacy of Doxorubicin Encapsulated in Stealth® Liposomes (Doxil®)Journal of Liposome Research, 1994
- Pharmacokinetic Study on the Mechanism of Tissue Distribution of Doxorubicin: Interorgan and Interspecies Variation of Tissue-To-Plasma Partition Coefficients in Rats, Rabbits, and Guinea PigsJournal of Pharmaceutical Sciences, 1984